Plasma protein levels and hepatocellular carcinoma: a Mendelian randomization study with drug screening implications
This study highlights the potential of Belinostat as a promising therapeutic agent for HCC. By modulating immune responses and tumor growth, Belinostat offers a novel approach to HCC treatment, warranting further clinical investigation to validate its efficacy and therapeutic potential.
Authors
- Jianwei Lan
- Quanyan Liu (ORCID: https://orcid.org/0000-0002-5353-0377)
- Yi Ning (ORCID: https://orcid.org/0000-0002-7737-580X)
- Longhui Xie
- Shuang Qin (ORCID: https://orcid.org/0000-0001-9264-6850)
- Dekun Song
- Pengpeng Liu (ORCID: https://orcid.org/0000-0003-3465-1402)
Institutions
- Hunan University of Science and Engineering (CN)
- Tianjin Medical University General Hospital (CN)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-04-19
- DOI
- https://doi.org/10.1007/s12672-025-02307-7
- Citations
- 1
- Primary Topic
- Polyamine Metabolism and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hainan Province